Listen to our CEO share his insights about BioSyent.


You can read the latest news about BioSyent, our products and our pipeline.

Nov 20, 2023
BioSyent Announces the Availability of Gelclair® in Canada
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of its new oncology supportive care product, Gelclair®, to wholesalers in Canada.
Oct 18, 2023
BioSyent Launches on World Menopause Day
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce the launch of, a comprehensive online platform designed to empower peri-menopausal and menopausal women across Canada.
Mar 07, 2023
BioSyent Announces Launch of New FeraMAX® Pd Maintenance 45
On the eve of International Women’s Day, BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd Maintenance 45 is BioSyent’s third product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system.
Aug 08, 2023
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to help them manage their symptoms.
September 29, 2021
Biosyent is undervalued, this investor says
If you’re looking for a pharma name with solid prospects you should be checking out Canadian company BioSyent. Portfolio manager Jason Del Vicario of Hillside Wealth Management says their new drug could be a big money-maker.
Apr 27, 2021
BioSyent: An Undervalued Canadian Healthcare Jewel
In a nutshell, we believe at current prices, markets are ignoring growth guided by the management. We feel BioSyent's strong financials, previous operational execution, and management's skin in the game makes it a buy.
Mar 31, 2021
Health Canada has approved the first acetaminophen and ibuprofen combination tablet in the country
GNM speaks with Dr. Hance Clarke about the benefits and risks to the newly approved acute pain drug.
Mar 26, 2021
Dr. Hance Clarke, Director of Pain Services at Toronto General Hospital talks to CTV about the efficacy of Combogesic®
Mar 24, 2021
Nardine Nakhla, University of Waterloo professor and community pharmacist discusses Combogesic®
Nardine Nakhla, University of Waterloo professor and community pharmacist discusses Combogesic® for acute pain management in the Pharmacy Practice + Business journal.
Mar 24, 2021
NewsTalk 1010 – Interview with Dr Hance Clarke